Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II study of montelukast sodium gel for acute radiation-induced rectal injury
CTR20223131Phase 2Active
- Sponsor
- Berrisen Pharmaceutical
- Start
- Apr 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of montelukast in radiation proctitis, Acute radiation proctitis (ARP), sponsored by Berrisen Pharmaceutical. Started Apr 2023; status: active.
02
Drugs
montelukast
03
Conditions
radiation proctitisAcute radiation proctitis (ARP)
Beyond the preview
Go deeper on CTR20223131.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20223131.